Big picture - Why invest in C4X Discovery Holdings plc
C4X Discovery Holdings plc Snapshot
C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.
The Company was founded as a spin-out from the University of Manchester and has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically.
C4X Discovery is using its unique proprietary technologies to build a pipeline of high quality small molecule drug candidates addressing valuable markets with high unmet medical need.
At present, C4X Discovery’s portfolio targets addiction, diabetes, inflammatory diseases (COPD and psoriasis) and oncology and includes small molecule versions of marketed biologics.
The Company's first drug candidate is an oral Orexin-1 antagonist for the treatment of addiction, with its primary indication as an aid to smoking cessation. It is currently in pre-clinical development with a regulatory submission to conduct a Phase I clinical trial planned for late 2016. C4X Discovery is currently expanding its pipeline and expects to ultimately initiate more than 4 therapeutic projects each year at steady state.
(Inititated Nov 15)
- Market size in 2018; Source: GBI Research 2012
- Market size in 2017; Source: Visiongain, Asthma and COPD Therapies: World Market 2013-2023
- Market size in 2017; Source: Visiongain, Diabetes-Treatments-World-Drug-Market-2013-2023
- Market size in 2018; Source Visiongain, Psoriasis Treatment; Decision Resources
For more information please click here
C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates.
The Company has a unique software platform for determining the flexible 3D shapes of drug molecules from experimental in vitro data and this enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas.
Targets are selected through traditional industry methods and C4X Discovery’s proprietary Taxonomy3® platform, which enables the discovery of targets that cause disease, rather than those that are simply associated with its symptoms. This provides the best starting point for drug discovery, biomarker identification and patient stratification, and significantly improves the chances of clinical success. The measurement, analysis and use of dynamic 3D-shapes is at the heart of C4XD's drug discovery engine. The focus and clarity that these data provide allows the Company to make rapid progress in developing new and better drugs at a fraction of the cost, compared to best industry practice.
For more information, please click here
Sam Williams, PhD - Interim Chairman (Non-Executive Director)
Sam has 20 years’ experience in the biotechnology sector, both as a top-ranked equity analyst in the City and, subsequently, as an entrepreneur and chief executive. Since 2007, he has been CEO of Modern Biosciences, a London-based company developing novel agents for the treatment of chronic, inflammatory diseases. Prior to that, Sam spent ten years in finance, most notably at Lehman Brothers, during which time he was ranked the number one European biotechnology equity analyst by Institutional Investor magazine three years in a row. As well as being CEO of MBS, Sam is a board member of the UK BioIndustry Association (BIA), a non-executive director of Diurnal Group plc and serves on the Translational Awards Advisory Committee of the British Heart Foundation (BHF). Sam has a PhD from Cambridge University and an MA in Pure and Applied Biology from Oxford University.
Clive Dix, PhD - Chief Executive Officer (Director)
Clive has more than 30 years' experience in life science research, with over 20 years in senior pharmaceutical industry positions, and a degree and PhD in Pharmacology. His expertise includes an in-depth understanding of all facets of drug discovery and development, a broad knowledge of the science and commercial landscape of a variety of therapeutic areas, and solid experience of the pharmaceutical business and finance community supporting the sector.
Clive was co-founder and Chief Executive of Convergence Pharmaceuticals Ltd, which was acquired by Biogen in Jan 2015.
Clive was previously co-founder and Chief Executive of PowderMed Ltd, a vaccines development company acquired by Pfizer in November 2006; before that he was Senior Vice President, Research and Development and a Board member of PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003. Clive began his career in industry at Ciba-Geigy and then GlaxoWellcome, where he left as UK Research Director in 2001. Clive is a recent past Chairman of the BioIndustry Association (BIA), is currently Non-Executive Chairman of Touchlight Genetics Ltd and Centauri Ltd, and Non-Executive Member of the Medicines Discovery Catapult Board.
Craig Fox, PhD - Chief Scientific Officer (Director)
Craig is an experienced biologist having worked on and managed many drug discovery and development projects during the last 18 years, from initial target selection right through to investigating clinical efficacy and safety in Ph II patient studies. Prior to joining C4X Discovery, Craig was director of Respiratory Research at Pulmagen Therapeutics, a clinical stage company spun-out of Argenta in 2010. Craig was part of the Etiologics Team that merged with Argenta Discovery in 2004 and prior to this he worked for Bayer as a Research Scientist. Craig has a PhD from Birmingham University and a first class biochemistry degree from the University of Surrey.
Brad Hoy - Chief Financial Officer (Director)
Brad has more than 20 years’ experience in the pharmaceutical and biotechnology industries and has held a number of senior financial and general management positions in both the UK and US. Previously, Brad was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed specialty pharmaceutical company, Chief Executive Officer of Xcellsyz Limited, a UK venture capital-backed life science company, and Senior Director of Geron Corporation’s stem-cell focused UK subsidiary. Brad is a co-founder of Seven Hills Venture Partners, a life sciences advisory firm, and currently serves on the Board of Directors for e-Therapeutics plc.
Harry Finch, PhD - Non-Executive Director
Harry has significant experience within the pharmaceutical industry, specialising in drug discovery and development. Currently he is an independent consultant working with a variety of small biotech companies and investors, the majority of which are in the oncology arena. Harry is also a non executive director of Pulmocide Therapeutics.
Following attaining a PhD in Organic Chemistry, Harry worked at Ciba-Geigy AG (Now Novartis AG) and Roche Allen & Hanburys Limited, before joining GlaxoWellcome plc where he became Director of Chemistry.
Harry is an expert in the respiratory area of the pharma industry and is co-inventor of GSK's successful asthma drug salmeterol (Serevent). In addition, he has worked across a range of therapeutic areas and at several biotechnology companies including Ribotargets, Vernalis, Argenta and Pulmagen.
Alex Stevenson, PhD - Non-Executive Director
Alex has a proven track record in identifying, investing and growing business within the pharmaceutical sector. He began his career as a scientist, working in research and for a NYSE quoted drug development company, before moving into early stage pharmaceutical and healthcare investments. He has fulfilled board level investment and operational management roles. He is Chief Scientific Officer at 4d pharma plc.
From 2008, he was a director and shareholder in Aquarius Equity Partners Limited. Aquarius Equity Partners Limited invested in C4XD in 2008, when Alex joined the board as a non-executive director. Prior to joining Aquarius Equity Partners Limited, Alex worked for IP Group plc where he specialised in life science investments, identifying, developing and advising a number of companies in its portfolio, some of which went on to list on AIM.
Alex has been involved in a number of private and public companies, including Nanoco Group plc, admitted to AIM in 2009; Retroscreen Virology Group plc admitted to AIM in 2012; Tissue Regenix Group plc admitted to AIM in 2010; Auralis Limited, which, after investment through Aquarius Equity Partners Limited, delivered a 7 fold return through to its trade sale to ViroPharma Inc in 2010; 4d pharma plc, admitted to AIM in 2014.
For information on the management team, please click here
C4X Discovery Holdings PLC
53 Portland Street
+44 (0)161 235 5085
Nominated Advisor and Broker
Panmure Gordon (UK) Limited (NOMAD)
One New Change, London EC4M 9AF
Telephone: +44 (0)20 7886 2500
Auditors and Tax Advisors
1 The Embankment, Neville Street, Leeds LS1 4DW
Telephone: +44 (0)113 231 3000
Capita Registrars Ltd
The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU
Telephone: 0871 664 0300*, Overseas: +44 (0) 20 8639 3399
*Calls to 0871 numbers are charged at 10 pence per minute plus network extras. Lines are open from 8:30am to 5:30pm UK time, Monday to Friday.
Schofield Sweeney LLP
Springfield House, 76 Wellington Street, Leeds LS1 2AY
Telephone: +44 (0)1132 206270
41 Lothbury, London, EC2R 7HG
Telephone: +44 (0)20 3709 5700